Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · IEX Real-Time Price · USD
14.98
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
15.07
+0.09 (0.60%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
DAWN Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for DAWN stock have an average target of 38, with a low estimate of 33 and a high estimate of 44. The average target predicts an increase of 153.67% from the current stock price of 14.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DAWN stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $40 | Buy | Maintains | $40 | +167.02% | Jul 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +167.02% | Jun 20, 2024 |
| Needham | Needham | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +120.29% | Jun 19, 2024 |
| Needham | Needham | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +120.29% | May 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $40 | Strong Buy | Maintains | $50 → $40 | +167.02% | May 7, 2024 |
Financial Forecast
Revenue This Year
16.15M
Revenue Next Year
89.42M
from 16.15M
Increased by 453.67%
EPS This Year
-2.77
from -2.37
EPS Next Year
-2.19
from -2.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.4M | 142.0M | 486.3M | 485.9M | 765.0M |
| Avg | 16.2M | 89.4M | 252.3M | 378.5M | 573.4M |
| Low | 6.6M | 30.5M | 151.9M | 285.2M | 408.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 779.2% | 443.8% | 92.6% | 102.1% |
| Avg | - | 453.7% | 182.2% | 50.0% | 51.5% |
| Low | - | 88.7% | 69.9% | 13.0% | 7.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.67 | -1.63 | 0.62 | 1.06 | 2.91 |
| Avg | -2.77 | -2.19 | -0.83 | 0.34 | 1.71 |
| Low | -3.02 | -2.94 | -2.41 | -0.17 | 0.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 758.9% |
| Avg | - | - | - | - | 404.2% |
| Low | - | - | - | - | 140.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.